Approvals Big Thing Biotech Columnist Fda Feuerstein
Senior columnist Adam Feuerstein says post-FDA approval trading is the next big thing to watch in biotech.
YahooFinance | August 3, 2012
Tags:. .feuerstein. .biotech. .columnist. .fda. .approvals